Article originally published in PLC Life Sciences Handbook 2012
M&A in the life sciences sector has remained robust, driven by factors such as:
- „„ The need to replenish shrinking product pipelines.
- „„ The need to maintain revenues as patents on top-selling
- products expire.
- „„ The strategic diversification of business lines.
- „„ Expansion into emerging markets.
Unique features of research, development and commercialisation of products and technologies in the life sciences sector give rise to a multitude of issues across a broad range of legal and commercial fields. Therefore, it is essential for life sciences M&A teams to include counsel who are experienced in identifying and resolving sector-specific issues across a range of practice areas. This will ensure smooth implementation of the commercial deal.
This article illustrates how a complex and evolving legal and regulatory environment gives rise to unique challenges for those engaged in European M&A in the life sciences sector, by analysing a hypothetical M&A. In particular, it examines:
- „„ A life sciences M&A case study.
- „„ Due diligence and its impact.
- „„ Intellectual property issues.
- „„ Structuring the deal.
- „„ European competition laws.
- „„ Anti-corruption laws.
- „„ Employment issues.
- „„ Tax issues.
Read the complete article here